30
Participants
Start Date
September 21, 2023
Primary Completion Date
March 31, 2025
Study Completion Date
July 31, 2029
Daratumumab
Daratumumab will be administered by SC injection.
Bortezomib
Bortezomib dose will be calculated using the patient's actual body surface area (BSA) at baseline and will be administered by subcutaneous (SC) injection.
Lenalidomide
Lenalidomide will be administered by oral route.
Teclistamab
Teclistamab will be administered by SC injection.
Talquetamab
Talquetamab will be administered by subcutaneous (SC) injection.
Hospital Doce de Octubre, Madrid
Hospital Germans Trials i Pujol, Badalona
Hospital Clinic i Provincial de Barcelona, Barcelona
Hospital Virgen de la Arrixaca, Murcia
Clinica Universidad de Navarra, Pamplona
Hospital Universitario de Salamanca, Salamanca
H. Universitario Marqués de Valdecilla, Santander
Complejo Hospitalario Santiago (CHUS), Santiago de Compostela
Hospital Vírgen del Rocío, Seville
Hospital Universitari i Politecnic la Fe, Valencia
Janssen Pharmaceutica N.V., Belgium
INDUSTRY
PETHEMA Foundation
OTHER